CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 78 enrolled / 78 target
Drug / intervention
Isradipine +1 moredrug
Likely dose
15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03083353
NCT03083353Early Ph 1CompletedOn Track (1.0/mo)Completion was 36mo ago
CompareCT.gov

Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Jasper A. Smits·interventional·Posted Mar 20, 2017·Updated Jun 15, 2026

In Brief

A Early Phase 1 clinical trial evaluating Isradipine and Cue Exposure for Nicotine Dependence and 5 related conditions. Completed, enrolled 78 participants across 1 site.

Detailed Summary

The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence, Smoking, Cigarette, Smoking Cessation, Smoking Behaviors, Smoking Reduction, Craving
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Early Ph 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 20, 2017
Enrollment StartJan 22, 2020
Primary CompletionJun 14, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 9.3 years ago

Arms & Interventions

isradipineexperimental

Participants will receive 15mg of immediate release isradipine.

Drug: IsradipineBehavioral: Cue Exposure
placeboplacebo_comparator

Participants will receive a placebo pill identical in appearance to isradipine.

Behavioral: Cue Exposure

Interventions

Isradipinedrug

Isradipine will be administered 90 minutes prior to the initiation of cue exposure.

Cue Exposurebehavioral

Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.